Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study

BACKGROUND: The SAKK 17/16 study showed promising efficacy data with lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma. Here, we evaluated long-term outcome and analyzed the impact of lurbinectedin monotherapy on the tumor microenvironment at the cellular an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mark, M., Rusakiewicz, S., Früh, M., Hayoz, S., Grosso, F., Pless, M., Zucali, P., Ceresoli, G.L., Maconi, A., Schneider, M., Froesch, P., Tarussio, D., Benedetti, F., Dagher, J., Kandalaft, L., von Moos, R., Tissot-Renaud, S., Schmid, S., Metaxas, Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271468/
https://www.ncbi.nlm.nih.gov/pubmed/35427834
http://dx.doi.org/10.1016/j.esmoop.2022.100446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271468/
https://www.ncbi.nlm.nih.gov/pubmed/35427834
http://dx.doi.org/10.1016/j.esmoop.2022.100446

Ejemplares similares